• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    United Therapeutics Corporation - Common Stock (NQ:UTHR)

    532.94 +13.93 (+2.68%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 992,955
    Open 519.79
    Bid (Size) 494.67 (40)
    Ask (Size) 550.00 (120)
    Prev. Close 519.01
    Today's Range 511.99 - 533.12
    52wk Range 291.22 - 609.35
    Shares Outstanding 44,891,523
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    UTHR Q2 2026 Deep Dive: Product Pipeline Developments Offset Competitive Pressures
    Biotechnology company United Therapeutics (NASDAQ:UTHR) beat Wall Street’s revenue expectations in Q2 CY2026, but sales fell by 1.9% year on year to $783.3 m... 
    Via StockStory
    News headline image
    United Therapeutics Q2 Earnings Call Highlights ↗
    United Therapeutics (NASDAQ:UTHR) reported second-quarter 2026 revenue of approximately $783 million, essentially flat from the first quarter, as competitive pressure affected sales of its nebulized... 
    Via MarketBeat
    Topics Earnings

    Performance

    YTD
    +7.3%
    +7.3%
    1 Month
    -2.6%
    -2.6%
    3 Month
    -10.7%
    -10.7%
    6 Month
    +10.4%
    +10.4%
    1 Year
    +74.8%
    +74.8%

    More News

    Read More
    United Therapeutics (NASDAQ:UTHR) Tumbles as Q2 Revenue Misses Despite EPS Beat ↗
    Via Chartmill
    News headline image
    United Therapeutics (NASDAQ:UTHR) Surprises With Q2 CY2026 Sales
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    Earnings To Watch: United Therapeutics (UTHR) Reports Q2 Results Tomorrow
    Via StockStory
    News headline image
    United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Acquires Thymmune Therapeutics
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Q1 Earnings Outperformers: United Therapeutics (NASDAQ:UTHR) And The Rest Of The Therapeutics Stocks
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    These 3 Stocks Lowered Their Share Counts Drastically in Q1 ↗
    Via MarketBeat
    News headline image
    1 Cash-Producing Stock with Exciting Potential and 2 We Ignore
    Via StockStory
    Topics Energy
    News headline image
    What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    2 Mid-Cap Stocks on Our Buy List and 1 We Turn Down
    Via StockStory
    Topics Credit Cards
    News headline image
    United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call
    Via StockStory
    Topics Earnings
    News headline image
    United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
    From United Therapeutics Corporation
    Via Business Wire

    Frequently Asked Questions

    Is United Therapeutics Corporation - Common Stock publicly traded?
    Yes, United Therapeutics Corporation - Common Stock is publicly traded.
    What exchange does United Therapeutics Corporation - Common Stock trade on?
    United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for United Therapeutics Corporation - Common Stock?
    The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
    What is the current price of United Therapeutics Corporation - Common Stock?
    The current price of United Therapeutics Corporation - Common Stock is 532.94
    When was United Therapeutics Corporation - Common Stock last traded?
    The last trade of United Therapeutics Corporation - Common Stock was at 08/06/26 04:00 PM ET
    What is the market capitalization of United Therapeutics Corporation - Common Stock?
    The market capitalization of United Therapeutics Corporation - Common Stock is 23.92B
    How many shares of United Therapeutics Corporation - Common Stock are outstanding?
    United Therapeutics Corporation - Common Stock has 24B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.